scispace - formally typeset
R

Raffaele Bruno

Researcher at University of Pavia

Publications -  322
Citations -  14690

Raffaele Bruno is an academic researcher from University of Pavia. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 52, co-authored 275 publications receiving 11262 citations. Previous affiliations of Raffaele Bruno include University of Modena and Reggio Emilia.

Papers
More filters
Journal Article

The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?

TL;DR: Patients treated with a lamivudine-containing highly active antiretroviral therapy regimen starting their first HAART regimen showed a significantly lower level of alanine aminotransferase over follow-up and a significantly reduced risk of liver-related morbidity/mortality.
Journal ArticleDOI

Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis.

TL;DR: Screening for HBV should be considered before chemotherapy and prophylaxis with lamivudine can reduce the incidence of HBV reactivation as well as HBV-related morbidity and mortality.
Journal ArticleDOI

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Aimilia Karampatou, +87 more
TL;DR: Ovarian senescence in women of childbearing age who are HCV+ is associated with a lower chance of live birth, greater risk of infertility, gestational diabetes, pre-eclampsia and miscarriage, and such risks could be positively influenced by successful HCV cure.
Journal ArticleDOI

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Salvatore Petta, +192 more
TL;DR: The findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials.